A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
Memantine is a therapeutic agent that represents a unique class of Alzheimer's disease (AD) treatment options. A once daily (QD) dosing regimen in an AD population would simplify administration for the caregiver. The purpose of this study is to evaluate the safety and efficacy of modified release memantine taken once daily in outpatients with moderate-to-severe AD on a concurrent AChEI.
Inclusion Criteria:
Exclusion Criteria:
Saint Loius, Missouri 63104, United States
Buenos Aires, Buenos Aires 1419HDN, Argentina
Buenos Aires, Buenos Aires C1062ABF, Argentina
Buenos Aires, Buenos Aires C1117ABE, Argentina
Buenos Aires, Buenos Aires C1122AAJ, Argentina
Buenos Aires, Buenos Aires C1126AAB, Argentina
Buenos Aires, Buenos Aires C1181ACH, Argentina
Buenos Aires, Buenos Aires C1209AAB, Argentina
Buenos Aires, Buenos Aires C1405CNF, Argentina
Buenos Aires, Buenos Aires C1413FWO, Argentina
Buenos Aires, Buenos Aires C1419AHN, Argentina
Buenos Aires, Buenos Aires C1425AGP, Argentina
Buenos Aires, Buenos Aires C1425BPK, Argentina
Buenos Aires, Buenos Aires C1428AQK, Argentina
Buenos Aires, Buenos Aires C1428AQK, Argentina